Quantcast
Last updated on April 18, 2014 at 14:31 EDT

Latest Intravenous immunoglobulin Stories

2013-05-27 23:01:30

“Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease” is the new market research report added at ReportsnReports.com store. Dallas, Texas (PRWEB) May 27, 2013 “Immunoglobulins Market to 2019 Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for...

2013-02-21 08:34:03

KING OF PRUSSIA, Pa., Feb. 21, 2013 /PRNewswire/ -- CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen®, immune globulin intravenous [human]. The new vial size will simplify preparation and administration of the product when high volumes of it are required. Privigen is approved for the treatment of patients with primary immunodeficiency (PID), a group of rare and serious diseases of the immune system, and...

2013-02-12 08:31:37

PROVIDENCE, R.I., Feb. 12, 2013 /PRNewswire/ -- EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes' proven albumin-based half-life extension platform will create a safe and...

2013-01-31 16:27:15

BOCA RATON, Fla. and DREIEICH, Germany, Jan. 31, 2013 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM(TM), its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI). BIVIGAM is the first new intravenous immune globulin (IVIG) to be approved by the FDA with a validated assay for measuring potential...

2013-01-10 16:23:10

WASHINGTON, Jan. 10, 2013 /PRNewswire/ -- The Immune Deficiency Foundation (IDF), the national patient organization dedicated to improving the lives of persons with primary immunodeficiency diseases (PIDD), is proud to announce that the Medicare IVIG Access Act (HR 1845) was signed into law today, January 10, 2013, by President Obama. HR 1845 provides for a demonstration project to examine the benefits of providing coverage and payment for items and services necessary to administer...

2013-01-08 08:29:32

SAN DIEGO, Jan. 8, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (STI; OTCBB: SRNE) today announced that it has acquired worldwide rights that will allow for the application of STI's industry leading antibody library technology for the production of recombinant Intravenous immunoglobulins (rIVIG). Global sales of IVIG products exceeded $5 billion in 2012 and are projected to grow for the foreseeable future. "With the acquisition of the proprietary rights to the rIVIG technology, we now...

2012-12-21 20:20:57

WASHINGTON, Dec. 21, 2012 /PRNewswire-USNewswire/ -- The Immune Deficiency Foundation (IDF), the national patient organization dedicated to improving the lives of persons with primary immunodeficiency diseases (PIDD), is elated to announce that the Medicare IVIG Access Act (HR 1845) has passed in both the U.S. House of Representatives and Senate, allowing the legislation to be signed into law by the President. In the U.S., there are approximately 250,000 people diagnosed with primary...

2012-12-20 12:27:34

DREIEICH, Germany and BOCA RATON, Fla., Dec. 20, 2012 /PRNewswire/ -- Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for BIVIGAM(TM) for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA). BIVIGAM is the first polyspecific intravenous immune globulin manufactured in the U.S. by Biotest Pharmaceuticals Corporation (BPC) at its Boca Raton, Florida facility. This product is being...

2012-12-19 16:23:36

WASHINGTON, Dec. 19, 2012 /PRNewswire/ -- The Immune Deficiency Foundation (IDF), the national patient organization dedicated to improving the lives of persons with primary immunodeficiency diseases (PIDD), praises the actions of the U.S. House of Representatives in passing the Medicare IVIG Access Act (HR 1845). In the U.S., there are approximately 250,000 people diagnosed with PIDD, and thousands more go undetected. PIDD occurs in patients born with an immune system that either is absent...

2012-11-23 10:52:09

Immune globulin replacement began decades ago as a treatment for patients who could not make their own protective antibodies, but has proven to have much broader benefits than originally expected. With new uses regularly being discovered for this limited and expensive resource, including as a potential treatment for Alzheimer's disease, now is the time to discover exactly how intravenous immune globulin (IVIG) treatments work, and to engineer a protein that can provide similar benefits,...